D-tagatose-based compositions and methods for preventing and treating atherosclerosis, metabolic syndrome, and symptoms thereof

Abstract

Pharmaceutical compositions including D-tagatose along with a stilbene or stilbenoid component, or a salt or derivative thereof. Methods of prophylaxis and therapy by administering to a mammal a pharmaceutically effective amount of D-tagatose, optionally in combination with a stilbene or stilbenoid component, or a salt or derivative thereof to prevent or treat atherosclerosis, the metabolic syndrome, obesity, or diabetes.

1 - 21 . (canceled) 
     
     
         22 . A composition comprising a pharmaceutically effective amount of a first pharmaceutically active drug which comprises D-tagatose, or a pharmaceutically acceptable salt, sugar alcohol, hydrate, solvate, ester, amide, or prodrug thereof, and a pharmaceutically effective amount of a second pharmaceutically active drug which comprises a stilbene or stilbenoid component or any pharmaceutically acceptable salt, alcohol, hydrate, ester, amide, polymorph, isomer, or prodrug or combination thereof, wherein the composition is capable of decreasing a level of a triglyceride, a low-density lipoprotein, or a cholesterol in a subject. 
     
     
         23 . The composition of  claim 22 , wherein the second pharmaceutically active drug comprises a stilbene or stilbenoid component, or any pharmaceutically acceptable salt thereof. 
     
     
         24 . The composition of  claim 23 , wherein the stilbene or stilbenoid component comprises resveratrol or a resveratrol derivative, or a combination thereof. 
     
     
         25 . The composition of  claim 24 , wherein the resveratrol derivative comprises a resveratrol dimer. 
     
     
         26 . The composition of  claim 25 , wherein the resveratrol dimer comprises resveratrol trans-dehydrodimer, resveratrol (E)-dehydrodimer 11′-O-β-D-glucopyranoside, resveratrol (E)-dehydrodimer 11-O-β-D-glucopyranoside and viniferins, or an isomer thereof, or a combination thereof. 
     
     
         27 . The composition of  claim 22 , wherein the composition is effective to decrease a total serum triglyceride level in a patient's blood by about 1% to about 60%. 
     
     
         28 . The composition of  claim 22 , wherein the composition is effective to decrease a concentration of low-density lipoprotein in a patient's blood by about 0.1% to about 30%. 
     
     
         29 . The composition of  claim 22 , wherein the composition is effective amount to decrease plaque volume in a patient's arteries by about 0.1% to about 50%. 
     
     
         30 . The composition of  claim 24 , wherein the resveratrol derivative comprises trans-piceid. 
     
     
         31 . The composition of  claim 30 , wherein the amount of D-tagatose in the composition is effective to treat a disease associated with an abnormally increased level of a total serum triglyceride, a low-density lipoprotein, or a combination thereof. 
     
     
         32 . The composition of  claim 31 , wherein the disease is the metabolic syndrome, atherosclerosis, obesity, diabetes, or a combination thereof. 
     
     
         33 . The composition of  claim 22 , wherein the amount of D-tagatose in the composition is effective to reduce the severity of progression of a disease associated with an abnormally increased level of a total serum triglyceride, a low-density lipoprotein, or a combination thereof. 
     
     
         34 . The composition of  claim 33 , wherein the disease is the metabolic syndrome, atherosclerosis, obesity, diabetes, or a combination thereof.